Nektar Therapeutics has presented positive Phase II study results of NKTR-102 in patients with metastatic breast cancer.

NKTR-102, a topoisomerase I inhibitor, is designed using Nektar’s proprietary polymer conjugate technology and is being developed in multiple tumour settings.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

USC Norris Comprehensive Center Clinical Medicine associate professor Agustin Garcia said that NKTR-102 exhibits a high response rate and excellent clinical benefit rate in patients with metastatic breast cancer, and that anti-tumour activity is maintained in each of the poor prognosis subsets within the study.

“The data from the Phase II study also shows highly promising progression-free survival of 5.3 months and overall survival of 13.1 months in the every three week dose schedule, which was also very well-tolerated,” Garcia added.

The randomised two-stage study of single-agent NKTR-102 evaluated two 145mg/m² dose schedules of NKTR-102, every two weeks (q14d) and every three weeks (q21d), in 70 metastatic breast cancer patients.

In the trial, NKTR-102 achieved a confirmed objective response rate by RECIST of 29%, while 71% of patients showed no tumour progression.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company also plans to conduct a Phase III clinical trial of NKTR-102 in 840 metastatic breast cancer patients who have had prior treatment with anthracycline, taxane and capecitabine in either the adjuvant or metastatic setting.

The primary endpoint of the breast cancer outcomes with NKTR-102 study, expected to begin in December 2011, will be overall survival and secondary endpoints will include progression-free survival and overall response rate.